register free | resend password


ID: 1003703
recent pressrelease next pressrelease

(Thomson Reuters ONE) - REGULATED INFORMATIONGHENT, Belgium, 27 August 2009 - Ablynx [Euronext Brussels: ABLX],announced today its results for the six month period ending 30 June2009, which have been prepared in accordance with the IAS 34 'InterimFinancial Reporting' as adopted by the European Union.H1 2009 Highlights * ?101.8 million in cash, cash equivalents and financial assets at 30 June 2009 * 93% increase in revenues to ?11.9 million (2008: ?6.2 million) * Reported detailed positive Phase Ib results in patients for its anti-thrombotic Nanobody® ALX-0081 and progressed to an extended Phase 1b study * Ablynx's vWF Nanobody® programme for the treatment of thrombotic thrombocytopenic purpura (TTP) was granted orphan drug designation in both Europe and the USA * Announced a new preclinical development candidate, ALX-0061, a Nanobody® binding to IL6R, for the treatment of autoimmune and inflammatory diseases * Announced important technology developments in pulmonary delivery and novel proprietary half-life extension of Nanobodies® * Received a ?3 million milestone from Boehringer Ingelheim as part of the strategic alliance for the development and commercialisation of Nanobodies® * Novartis and Wyeth Pharmaceuticals both extended their research collaborations with Ablynx for a further 12 months * Ablynx strengthened its senior team with the appointment of a new Chief Scientific Officer, a Medical Director and a new Business Development Director * Increased staff to over 220 people by period end * Continued preparations for the move to new 7,000 m2 facility in mid-2010For more information, please contact:For international media enquiries:College Hill Life SciencesSue Charles, Justine Lamond,Dr. John McIntyret: +44 (0)20 7866 7857e: ablynx(at)collegehill.comAblynx:Dr. Edwin MosesChairman and CEOt: +32 (0)9 262 00 07m: +44 (0)7771 954 193 / +32 (0)473 39 50 68e: edwin.moses(at)ablynx.comEva-Lotta AllanChief Business Officert: +32 (0)9 262 00 75m: +32 (0)475 78 36 21 / +44 (0)7990 570 900e: eva-lotta.allan(at)ablynx.com announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Keywords (optional):

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: hugin
print pressrelease  send to a friend  

Date: 08/27/2009 - 18:00
Language: English
News-ID 1003703
Character count: 0
Firma: Ablynx
Ansprechpartner: Feedback to about Pressrelease-id:
Stadt: London


Number of hits: 213


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 61

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.